Lincoln Pharmaceuticals Ltd (IN:LINCOLN)
:LINCOLN
Want to see IN:LINCOLN full AI Analyst Report?
LINCOLN Stock Chart & Stats
₹496.60
-₹14.55(-1.74%)
At close: 4:00 PM EST
₹496.60
-₹14.55(-1.74%)
Day’s Range― - ―
52-Week Range₹439.95 - ₹731.50
Previous CloseN/A
Volume57.32K
Average Volume (3M)1.66K
Market Cap
₹12.93B
Enterprise Value₹13.26B
Total Cash (Recent Filing)₹2.32B
Total Debt (Recent Filing)₹668.00K
Price to Earnings (P/E)8.5
Beta1.05
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)14.28
Shares Outstanding20,029,728
10 Day Avg. Volume3,133
30 Day Avg. Volume1,664
Financial Highlights & Ratios
PEG Ratio-1.14
Price to Book (P/B)1.65
Price to Sales (P/S)1.77
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)72
Revenue Forecast (FY)₹8.82B
Bulls Say, Bears Say
Bulls Say
Very Low Debt / Strong Balance SheetNear-zero total debt and a minimal debt-to-equity profile provide durable financial flexibility, lowering solvency risk and funding costs. This supports multi-year investments, capacity expansion, and resilience to cyclical shocks without needing external financing, aiding long-term stability.
Improved Free Cash Flow GenerationA large rebound in free cash flow and FCF covering ~79% of net income strengthens self-funding capacity for capex, product launches, and shareholder returns. Sustained FCF reduces refinancing needs and enables strategic options, improving long-term capital allocation flexibility.
High Gross Margins & Steady Revenue GrowthConsistently high gross margins (>50%) and recurring revenue growth indicate a resilient product mix and pricing power versus input cost volatility. This structural profitability buffer supports reinvestment, R&D, and higher operating leverage over multiple quarters to years.
Bears Say
Margin CompressionMaterial deterioration in EBITDA and net margins signals sustained cost or pricing pressure that can erode cash generation and return on invested capital. If structural, margin compression reduces room for reinvestment and increases sensitivity to revenue slowdowns over coming quarters.
Operating Cash Flow Lags Net IncomePersistent operating cash shortfall vs. net income indicates working-capital volatility (receivables/inventory) that can limit cash available for growth or dividends. Over multiple quarters this can force conservative spending or reliance on financing despite healthy accounting profits.
Softer Earnings Trend (EPS Decline)Negative EPS growth signals pressure on core earnings momentum, which can reflect pricing, mix, or rising SG&A and impacts sustainable returns to shareholders. Continued EPS decline could erode investor optionality for funding R&D or acquisitions without dilutive financing.
Lincoln Pharmaceuticals Ltd News
LINCOLN FAQ
What was Lincoln Pharmaceuticals Ltd’s price range in the past 12 months?
Lincoln Pharmaceuticals Ltd lowest stock price was ₹439.95 and its highest was ₹731.50 in the past 12 months.
What is Lincoln Pharmaceuticals Ltd’s market cap?
Lincoln Pharmaceuticals Ltd’s market cap is ₹12.93B.
When is Lincoln Pharmaceuticals Ltd’s upcoming earnings report date?
Lincoln Pharmaceuticals Ltd’s upcoming earnings report date is May 21, 2026 which is in 18 days.
How were Lincoln Pharmaceuticals Ltd’s earnings last quarter?
Lincoln Pharmaceuticals Ltd released its earnings results on Feb 12, 2026. The company reported ₹14.279 earnings per share for the quarter, beating the consensus estimate of N/A by ₹14.279.
Is Lincoln Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Lincoln Pharmaceuticals Ltd’s price is currently Overvalued.
Does Lincoln Pharmaceuticals Ltd pay dividends?
Lincoln Pharmaceuticals Ltd pays a Annually dividend of ₹1.8 which represents an annual dividend yield of 0.37%. See more information on Lincoln Pharmaceuticals Ltd dividends here
What is Lincoln Pharmaceuticals Ltd’s EPS estimate?
Lincoln Pharmaceuticals Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lincoln Pharmaceuticals Ltd have?
Lincoln Pharmaceuticals Ltd has 20,029,728 shares outstanding.
What happened to Lincoln Pharmaceuticals Ltd’s price movement after its last earnings report?
Lincoln Pharmaceuticals Ltd reported an EPS of ₹14.279 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.516%.
Which hedge fund is a major shareholder of Lincoln Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in IN:LINCOLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics. It provides products in the areas of cough and cold, anti-allergic, and anti-asthmatics; sterile ophthalmic eye drops and ointment; anti-malarial; vitamins, minerals, and antioxidants; anti-bacterial, anti-viral, and anti-fungal vitamins; analgesic and anti-pyretic; anti-psychotic, anti-convulsant, anti-depressant, and anti-diabetic; cardiac anti-hypertensives, and diuretic; and anti-diarrheal, anti-spasmodic, and laxative. The company also offers branded generics. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Jagsonpal Pharmaceuticals Ltd.
―
Syncom Formulation (India) Ltd.
―
Venus Remedies Limited
―
Wanbury Limited
―